Cell-penetrating peptides (CPPs) are short peptides (fewer than 30 amino acids) that have
been predominantly used in basic and preclinical research during the last 30 years. Since …

In today's modern era of medicine, macromolecular compounds such as proteins, peptides
and nucleic acids are dethroning small molecules as leading therapeutics. Given their …

The presence of cell and tissue barriers together with the low biomembrane permeability of
various therapeutics often hampers systemic drug distribution; thus, most of the available …

Protein therapy holds great promise for treating a variety of diseases. To act on intracellular
targets, therapeutic proteins must cross the plasma membrane. This has previously been …

Neurodegenerative diseases are common, incurable neurological disorders with high
prevalence, and lead to memory, movement, language, and intelligence impairments …

Efficient intracellular drug delivery and target specificity are often hampered by the presence
of biological barriers. Thus, compounds that efficiently cross cell membranes are the key to …

With more than ten new FDA approvals since 2001, peptides are emerging as an important
therapeutic alternative to small molecules. However, unlike small molecules, peptides on the …

Efficient intracellular trafficking and targeted delivery to the site of action are essential to
overcome the current drawbacks of cancer therapeutics. Cell Penetrating Peptides (CPPs) …

Arginine-rich cell-penetrating peptides do not enter cells by directly passing through a lipid
membrane; they instead passively enter vesicles and live cells by inducing membrane …

The hydrophilic nature of peptides and proteins renders them impermeable to cell
membranes. Thus, in order to successfully deliver peptide and protein-based therapeutics …